A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are ...

Innovative polatuzumab vedotin plus R-CHP therapy reshapes treatment of older adult patients with diffuse large B-cell lymphoma.

What Is B-Cell Lymphoma? B-cell lymphoma is a cancer that forms in your white blood cells called lymphocytes. These cells are made by your lymphatic system, which plays an important role in immunity.

The following is a summary of “Identification of molecular clusters and a risk prognosis model for diffuse large B-cell ...

Discover how innovative lymphoma treatments are transforming patient outcomes, from targeted therapies to immunotherapy ...

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk ...

17% had B-cell lymphoma, 17% had leukemia and 8% had Hodgkin lymphoma. The median age of participants was 47. By week four, the response rate with ELA026 was 100% in the frontline setting ...

Discover the long-term results of CAR T-cell therapy, with and without stem cell transplantation, for relapsed lymphoma ...

The primary endpoint of the trial is progression-free survival, with secondary endpoints including complete response rate, overall survival ... form of non-Hodgkin lymphoma, accounting for ...